Lumos Pharma Inc (LUMO)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer and Chairman John McKew - President and Chief Scientific Officer Lori Lawley - Chief Financial Officer Duke Pitukcheewanont - Chief Medical Officer Conference Call Participants Catherine Novack - Jones Trading Leland Gershell - Oppenheimer Charles Duncan - Cantor Fitzgerald Operator Good afternoon and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Programs Update Call. Currently, all participants are in a listen-only mode.
Lumos Pharma Inc (LUMO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lumos Pharma Inc ever had a stock split?
Lumos Pharma Inc Profile
| Biotechnology Industry | Healthcare Sector | Richard J. Hawkins CEO | NASDAQ (NMS) Exchange | 55028X109 CUSIP |
| US Country | 30 Employees | - Last Dividend | 19 Mar 2020 Last Split | 11 Nov 2011 IPO Date |
Overview
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company with a focus on the development and commercialization of innovative therapeutics for rare diseases. Positioned at the forefront of addressing unmet medical needs, Lumos Pharma is dedicated to bringing novel treatment options to patients afflicted with rare endocrine disorders. Headquartered in the vibrant city of Austin, Texas, Lumos Pharma leverages cutting-edge science and research to fuel its ambitions and aspirations in the rare disease therapeutic space.
Products and Services
- LUM-201 (Oral Growth Hormone Secretagogue Ibutamoren)
LUM-201 is Lumos Pharma's flagship product candidate, currently undergoing rigorous testing in a Phase 3 clinical trial. This innovative therapeutic agent is an oral growth hormone secretagogue designed to mimic the action of endogenous ghrelin in the body. By stimulating the secretion of growth hormone, LUM-201 aims to address the needs of patients suffering from idiopathic pediatric growth hormone deficiency. Such a deficiency can lead to various growth disorders in children, significantly impacting their quality of life. Additionally, LUM-201 is being investigated for its potential applications in treating other rare endocrine disorders, marking a significant step forward in providing comprehensive care to patients with rare diseases.
